NYSE:QGEN • NL0015002SN0
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for QIAGEN N.V. (QGEN).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-13 | Deutsche Bank | Upgrade | Hold -> Buy |
| 2026-02-06 | Stifel | Maintains | Hold -> Hold |
| 2026-02-06 | JP Morgan | Maintains | Overweight -> Overweight |
| 2026-02-06 | Citigroup | Maintains | Neutral -> Neutral |
| 2026-01-22 | Deutsche Bank | Downgrade | Buy -> Hold |
| 2025-12-15 | Barclays | Maintains | Overweight -> Overweight |
| 2025-12-11 | Citigroup | Downgrade | Buy -> Neutral |
| 2025-10-02 | Barclays | Maintains | Overweight -> Overweight |
| 2025-08-07 | UBS | Maintains | Neutral -> Neutral |
| 2025-06-26 | B of A Securities | Maintains | Buy -> Buy |
| 2025-06-24 | Barclays | Initiate | Overweight |
| 2025-04-21 | Baird | Maintains | Neutral -> Neutral |
| 2025-04-04 | Redburn Atlantic | Downgrade | Buy -> Neutral |
| 2025-02-19 | Baird | Downgrade | Outperform -> Neutral |
| 2025-02-07 | UBS | Maintains | Neutral -> Neutral |
| 2025-01-06 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2024-10-17 | HSBC | Downgrade | Buy -> Hold |
| 2024-08-02 | Baird | Maintains | Outperform -> Outperform |
| 2024-06-27 | Wolfe Research | Upgrade | Peer Perform -> Outperform |
| 2024-06-18 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-05-01 | Stifel | Maintains | Hold -> Hold |
| 2024-02-16 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
| 2024-02-08 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-02-08 | Citigroup | Maintains | Buy -> Buy |
| 2023-12-20 | JP Morgan | Maintains | Overweight -> Overweight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.965B -8.23% | 1.978B 0.66% | 2.09B 5.65% | 2.261B 8.18% | 2.39B 5.71% | 2.535B 6.07% | 2.826B 11.48% | 3.077B 8.88% | |
| EBITDA YoY % growth | 650.583M -17.08% | 698.225M 7.32% | 745.19M 6.73% | 836.41M 12.24% | 905.59M 8.27% | 978.35M 8.03% | 1.007B 2.93% | 1.05B 4.27% | |
| EBIT YoY % growth | 445.247M -22.73% | 494.957M 11.16% | 551.444M 11.41% | 642.32M 16.48% | 697.22M 8.55% | 763.5M 9.51% | 906.98M 18.79% | 994.81M 9.68% | |
| Operating Margin | 22.66% | 25.02% | 26.38% | 28.41% | 29.17% | 30.12% | 32.09% | 32.33% | |
| EPS YoY % growth | 2.18 -13.35% | 2.24 2.65% | 2.47 10.63% | 2.60 5.30% | 2.88 10.65% | 3.17 9.97% | 3.41 7.54% | 3.51 3.14% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.56 -3.89% | 0.65 2.62% | 0.67 3.92% | 0.70 12.18% | 0.61 8.89% | 0.70 7.42% | 0.73 8.96% | 0.76 8.97% | 0.68 12.12% | 0.75 7.97% | 0.78 7.74% | 0.80 5.79% |
| Revenue Q2Q % growth | 511.41M 5.78% | 564.69M 5.84% | 580.52M 9.00% | 592.78M 9.69% | 538.76M 5.35% | 595.67M 5.49% | 608.43M 4.81% | 627.65M 5.88% | 562.83M 4.47% | 621.12M 4.27% | 642.9M 5.67% | 657.4M 4.74% |
| EBITDA Q2Q % growth | 179.19M 3.77% | 205.6M -13.83% | 213.29M -25.27% | 222.57M -29.55% | 201.21M 12.29% | 221.7M 7.83% | 228.07M 6.93% | 235.27M 5.71% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 142.79M 10.88% | 166.59M 14.73% | 173.28M 22.84% | 182.23M 49.13% | 155.24M 8.72% | 179.5M 7.75% | 186.85M 7.83% | 195.55M 7.31% | N/A | N/A | N/A | N/A |
All data in USD
24 analysts have analysed QGEN and the average price target is 55.29 USD. This implies a price increase of 35.21% is expected in the next year compared to the current price of 40.89.
QIAGEN N.V. (QGEN) will report earnings on 2026-05-04, after the market close.
The consensus EPS estimate for the next earnings of QIAGEN N.V. (QGEN) is 0.56 USD and the consensus revenue estimate is 511.41M USD.
The number of analysts covering QIAGEN N.V. (QGEN) is 24.